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Background: For a significant number of patients with severe or refractory gastroesophageal reflux 
disease, maintenance treatment with omeprazole and reflux surgery (Nissen fundoplication) are 
alternative treatment options. In this study maintenance treatment with omeprazole is compared with 
open and laparoscopic Nissen fundoplication from a health-economic perspective. Methods: Meta­
analysis of published articles to assess effectiveness and simple decision-analytic techniques to combine 
costs and effects are used. Findings and assumptions are submitted to sensitivity analysis. Results: It is 
estimated that it costs approximately 1880 Dutch guilders to initially heal a patient with severe or 
refractory esophagitis with 40 mg omeprazole daily. When medical maintenance therapy was compared 
with surgery, it appeared that medical maintenance therapy with omeprazole (20-40 mg daily) for a 
prolonged period of time (more than 4 years) is less cost effective than a Nissen procedure. It is estimated 
that a laparoscopic Nissen will shift this so-called break-even point towards 1.4 years, mainly due to a 
shorter hospital stay. Conclusions: Although caution is required in drawing conclusions, it appears that 
replacing treatment with (laparoscopic) Nissen fundoplications in these patients might lead to substantial 
savings.
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Gastroesophageal reflux is a common problem in clinical 
practice, and it is estimated that ±5% of the adult Western 
population has it on a daily basis. Patients with gastro­
esophageal reflux disease (GERD) experience symptoms due 
to pathologic reflux, frequently resulting in complications. 
Despite the introduction of H2-receptor antagonists a certain 
percentage of GERD patients do not respond well to medical 
treatment. Omeprazole offers a new and highly effective 
treatment option for these patients and has become standard 
medical treatment for patients with grade-III or -IV 
esophagitis (Savary-Miller classification (1)) in The Nether- 
lands. Cessation of treatment, however, results in rapid 
relapse in almost all patients, necessitating prolonged or 
maintenance therapy. An alternative treatment option is 
surgery. The Nissen fundoplication is performed most 
frequently in The Netherlands. The introduction of a 
laparoscopic Nissen fundoplication might potentially lead 
to an increase in popularity, mainly due to a decrease in 
postoperative morbidity, resulting in a reduction of hospital 
stay. In this study medical treatment with omeprazole is 
compared with the open and the laparoscopic Nissen 
fundoplication, by means of cost-effectiveness analysis. 
The nature of the respective treatments and, accordingly, 
their outcome differ in many respects. Medical treatment is
aimed at reducing gastric acidity, whereas surgery is aimed at 
restoring lower esophageal sphincter pressure. Medical 
therapy is accompanied by possible side effects (2), and 
surgery by possible complications (3), but both are ultimately 
aimed at the healing and prevention of esophagitis. The 
absence of esophagitis is the central comparator, and this 
study and the results presented are restricted to this 
comparator.
The objective of this study is threefold: first, to assess the 
cost effectiveness of treatment with omeprazole during the 
‘healing phase’ in patients with severe GERD or patients 
unresponsive to treatment with H2 blockers, and secondly, to 
compare medical maintenance treatment with its surgical 
alternative (that is, the Nissen fundoplication) in respective 
patients. Finally, an attempt is made to estimate the cost 
effectiveness of a laparoscopic Nissen fundoplication. A 
further attempt is made to put the results into perspective 
(both medically and economically).
PATIENTS AND METHODS
Patients
In the assessment of the cost effectiveness of omeprazole 
during the ‘healing phase’ studies were included in which
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patients had esophagitis grade I or worse (Savary-Miller). A 
differentiation was made between refractory esophagitis and 
esophagitis that was not further specified. Refractory patients 
were defined as patients who underwent treatment with 
normal or higher dosages of Hz-receptor antagonists for at 
least 3 months but failed to respond to therapy. The medical 
results obtained in refractory patients are used in the 
calculation of cost effectiveness.
Surgery was also performed in patients with complaints for 
prolonged periods of time who were unresponsive to medical 
treatment. The severity of esophagitis as expressed in Savary- 
Miller gradings was not always known. Since long-term 
results of the Nissen procedure were analyzed, the results 
were mostly obtained in the pre-omeprazole era.
Estimation of cost effectiveness
Assessment of effectiveness of both medical and surgical 
treatment was established by means of meta-analysis. This 
was performed in accordance with ter Riet & Bouter (4). 
Articles were selected using CD-ROM-derived references 
(MEDLINE: 1966-March 1993). A correction was made for 
quality and significance of the published studies by means of a 
weighing procedure. Since information on all the weighing 
factors proposed by ter Riet & Bouter were not available, the 
following simplified weighing scheme is applied:
Design, in accordance with RCT principle 3 points
Analysis performed on basis of ‘intention 2 points 
to-treat* principle
Experimental group size >50 1 point
Number of drop-outs < 10% 1 point
Comparison versus placebo 1 point
Minimum weight 1 point
If weighted results do not differ statistically from the 
unweighted, unweighted results will be presented.
Effectiveness of medical treatment during the ‘healing 
phase’ was defined as: ‘the percentage of patients whose 
esophagitis was cured (gastroscopically proven grade 0)’. In 
the comparison of medical maintenance treatment with 
omeprazole versus the (laparoscopic) Nissen fundoplication, 
effectiveness was defined as; ‘the ability (of respective 
treatments) to retain patients in full remission of esophagitis 
during a certain period of time’, expressed in patient-years.
Costs were estimated using modeling techniques. Only 
direct medical costs due to treatment were regarded. Costs 
due to side effects or complications were ignored. Costs for 
medication were valued using market prices; other cost 
factors were estimated using (weighted) reimbursement data 
as proxies of actual costs. Information concerning the 
laparoscopic procedure was gathered by means of interviews 
with experts in the field. Both costs and effects are discounted 
at a 5% rate, in accordance with the Dutch guidelines (5). For 
cross-study comparison a second approach to discounting is 
chosen in which costs are discounted at a 5% rate and effects 
are not discounted (that is, 0%).
The level of the discount rate is varied from 2% to 8% in 
the final sensitivity analysis.
RESULTS
Cost effectiveness of omeprazole in the healing phase 
The analysis included 25 studies (6-31) with a total of 69 
results (healing rates). Results of the analysis are presented in 
Fig. 1 (unweighted results).
Weighing did not result in significant changes. The 
calculation of cost effectiveness is based on medical therapy 
with 40 mg omeprazole once daily (20 mg is suboptimal). It is 
assumed that assessment of healing (gastroscopy) takes place 
8 weeks after therapy initiation, which meets clinical practice 
in The Netherlands. On the basis of the meta-analysis 84% of 
all patients are cured during the first 8 weeks. Patients who do 
not respond well to therapy will receive an additional 4 weeks 
of treatment. After this period an additional gastroscopy will 
take place. Forty-eight per cent of these patients respond well 
to this prolonged therapy, resulting in a total healing rate of 
91% after 12 weeks. The remaining 9% are considered 
unresponsive to treatment with omeprazole, although it is 
reported that additional healing is achievable with higher 
doses.
The calculation of cost effectiveness of omeprazole 
treatment (40 mg) in severe or refractory esophagitis is based 
on:
Medication costs (on average per patient) Dfl.782.60* 
Costs due to gastroscopic assessment (on Dfl.935.75f 
average per patient)
Effectiveness (ability to cure) 91%
It will cost approximately 1880 Dutch guilders (1 
US$ = ±Dfl. 1.60) on average to initially heal esophagitis 
with omeprazole.
Cost effectiveness of omeprazole in the maintenance phase 
Once healing with omeprazole has been accomplished, 
cessation of treatment in patients with severe or refractory 
esophagitis will result in relapse of esophagitis in more than 
80% of all cases within 6 months (6,8). Maintenance 
treatment with H2-receptor antagonists is not likely to prevent 
relapse (31). Temporary cessation of maintenance therapy 
with omeprazole in patients with refractory esophagitis was 
accompanied by relapse of esophagitis in all patients (32). 
This implies that patients with refractory reflux esophagitis 
require maintenance treatment for prolonged periods of time, 
perhaps even for the rest of their lives. Studies on the efficacy 
of long-term treatment with omeprazole reveal its potential to
* Wholesale price per daily dose (40 mg) is Dfl. 11.98 (Oct. 
1992) + 6% VAT + Dfl. 11.50 per recipe (pharmacist’s expenses).
f Costs of gastroscopy are calculated as the weighed mean of 
reimbursements by National Health Insurance (NHI) and private 
insurers, The weighing correvsponds with the number of people 
insured by the respective insurances.
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20mg/ 4wks/n=659 
20mg/ 8wks/n=596
40mg/ 4wks/n=476 
40m g/ 8wks/n=527 
40mg/12wks/n=110
60mg/ 8wks/ n=47 
60mg/12wks/ n=47
20mg/ 4wks/ n=25 
20mg/ 8wks/ n=25
40mg/ 4wks/n=416 
40m g/ 8wks/n=439 
40mg/12wks/n=416
60mg/16wks/
0% 20% 40% 60% 80% 100%
Fig. 1. Effectiveness of omeprazole in the ‘healing phase’: dose- and duration-specific, n = experimental group size. * Refractory esophagitis 
with Barrett’s epithelium.
retain patients in full remission of esophagitis. Four studies months adds up to 1060 months (effectiveness = 88.3%). In
were found with follow-up periods ranging from 12 to 36 
months (23, 33-35). Three of them show little variation: 68%
the years to follow, patients who respond well to maintenance 
treatment continue to receive their efficacious dose and are 
to 73% of patients remained in remission of esophagitis for monitored once a year by means of gastroscopy. Since the 
the entire study period with 20 mg omeprazole once daily. In effects and costs are considered to be constant from then on, 
one study (23) all patients remained in remission, but this the cost effectiveness is constant for every future year, 
result is invalidated by its small sample size (n = 10) and is
therefore omitted. Relapses predominantly occurred during 
the first 6 to 9 months of maintenance treatment. Most 
relapses, however, responded well to an increase in dose to 
40 mg (33, 35).
For use of these results in the calculation of the cost- 
effectiveness ratio a conservative estimate is chosen, mainly 
because results are slightly invalidated by small sample sizes, 
moderately high drop-out rates, and limited follow-up 
periods. It is assumed that two-thirds of patients remain in e^ ec^veness ^rst Year
First 6 months 
Medication costs
Costs are due to gastroscopic assessment 
Second 6 months 
Medication costs
Costs due to gastroscopic assessment 
Effectiveness; ability to retain patients 
in remission (patient-years)
Dfl. 117,859 
Dfl. 43,254
Dii. 154,925 
Dfl. 14,418 
88.33
Dfl. 3,741
remission throughout maintenance treatment of whatever 
duration with 20 mg. The relapses in the remaining one-third 
are assumed to occur evenly divided in time (linearity 
assumption). Eighty per cent of these cases respond well to an 
increase in dose to 40 mg. These patients receive this dose for 
the entire maintenance period. Assessment of success (by
Consecutive years (93.33 patients) 
Medication costs
Costs due to gastroscopic assessment 
Effectiveness (patient-years)
Cost effectiveness consecutive years
Dfl. 278,103 
Dfl. 40,370 
93.33 
Dfl. 3,412
The cost-effectiveness ratio of consecutive years is lower
means of gastroscopy) takes place 6 months after therapy than the first because during the first year all 100 patients
initiation and at 12 months in patients who relapsed during the receive treatment and more gastroscopies are performed
first 6 months. Patients unresponsive to 40 mg are considered (higher costs) and because not all patients receive an
resistant to maintenance treatment with omeprazole. Calcula- efficacious dose during the first year (lower effectiveness),
tions are based on a cohort of 100 patients entering the Given these assumptions and results, one is now able to
maintenance phase after complete healing of esophagitis. The project the cost effectiveness of maintenance treatment over
total number of months in remission during the first 12 time (Table I).
Table I. Costs and effects of maintenance treatment with omeprazole (on the basis of a cohort of 100 patients) and the impact of discounting
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Years
Present value 
of cost*
Cumulative
effectst
Cumulative
effects^
C/E
ratio§
C/E
ratio||
Costs per 
patient^
1 330,456 88.33 88.33 3741 3741 3741
2 648,931 177.22 181.66 3576 3489 6791
3 967,405 261.87 274,99 3523 3355 9886
4 1,285,879 342.49 368.32 3497 3252 12,833
5 1,604,353 419.27 461.65 3482 3162 15,641
10 3,196,724 751.70 928.30 3451 2794 27,795
15 4,789,094 1012.17 1394.95 3441 2497 37,318
20 6,381,465 1216.25 1861.60 3436 2245 44,780
25 7,973,835 1376.16 2328.25 3433 2029 50,626
30 9,566.206 1501.45 2794.90 3432 1844 55,207
* Cumulative total costs (in Dutch guilders) in respective year, discounted at a 5% rate, 
t  Cumulative effects, expressed as (patient) years in remission of esophagitis, discounted at a 5% rate.
% Cumulative effects, expressed as (patient) years in remission of esophagitis, not discounted,
§ Cost effectiveness; cumulative costs (5%) divided by cumulative effects (5%). 
j| Cost effectiveness: cumulative costs (5%) divided by cumulative effects (0%).
^ Total costs (5%) to keep one patient in remission of esophagitis during a particular number of years: a patient has a statistical chance of 
93% that therapy will be successful.
The data show that it is costly to keep a patient in 
remission; for example, it will cost approximately 27,800 
Dutch guilders to keep a patient in remission for a period of 10 
years, given a statistical chance of 93.33% that medical 
therapy will be successful in this patient.
Cost effectiveness of anti-reflux surgery
To assess the effectiveness of the Nissen procedure, 23 
studies are reviewed (36-58). Unfortunately, not all studies 
present gastroscopic findings. The results of this review are 
summarized in Table II.
The studies indicate that the Nissen fundoplication is 
highly effective in controlling gastroesophageal reflux and its 
symptoms. Good to excellent results range from 67% up to 
92%. A more standardized outcome measure, the Visick
Diagnostic actions
2 x gastroscopy (pre- and post- 
operatively)*
(24-h pH-metry study) (manometry)t 
Personnel cost 
Surgeon 
Assistant 
Anesthesiologist^
Hospital’s residence 
10 days’ hospitalization^
2 outpatient control visits^
Total costs per operation 
Effectiveness
Dfl, 865.00
Dfl. 955.25
Dfl, 9307.65 
Dfl, 56.85 
Dfl. 11,182.45 
90.05%
As opposed to medical treatment, costs and effects of surgery 
do not relate to the same period of time. Since costs are only
grading (grade I or II), ranges from 83.3% up to 100%. The incurred in the first year but effects pertain to future years, 
percentage of patients who underwent a Nissen procedure and effects need to be discounted, to correct for time preferences 
who remained in remission during the entire period of the (see Table III), 
respective study ranges from 75% to 100%. There are minor 
indications that the efficacy of the procedure decreases with
time; however, results of studies with a long follow-up period Cost effectiveness of a laparoscopic Nissen fundo pi ¿cation 
(range, 1-20 years) are comparable to those with a shorter The first results of a large series of laparoscopic 
time span. On the basis of these results, we assume that the fundoplications (59) are promising. A total of 197 patients 
effectiveness of the Nissen fundoplication is constant in time, were operated on. At 3 months 67 patients underwent 
The percentage of patients in remission of esophagitis is 
calculated on the basis of individual cases. This resulted 
in an effectiveness of 90.5%. The last column in Table II 
gives an impression of the ‘healing capacity5 of the operation: 
if esophagitis was present preoperatively, the Nissen 
fundoplication resulted in healing of the esophagitis and 
keeping the patient in remission during the entire follow-up 
period in about 85% of all cases. This figure might be
regarded as a lower estimate and will be used in the sensitivity 
analysis.
The following costs are calculated on the basis of 
reimbursements to university hospitals:
* For calculation, see cost-effectiveness omeprazole, 
f 24-h pH-metry and manometry were not reimbursed by insurers 
in The Netherlands at the time of this study.
t Calculated as the weighed mean of reimbursements by NHI 
(0.62 * (Dfl. 420 (surgeon) + Dfl. 175 (assistant) + Dfl. 175 
(anesthesiologist))) and private health insurers (0.38 * (Dfl. 932 
(surgeon) + Dfl. 319 (anesthesiologist))).
§ Calculated as the weighed reimbursement for a treatment day, 
the use of an operating room included; 10 days is the average length 
of admission in Thé Netherlands.
% Based on the weighed reimbursement of a reference card (NHI: 
Dfl. 40.50) and two consultations for the privately insured (first visit, 
Dfl. 51.00; second visit, Dfl. 32.50)
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Table II. The effectiveness of the Nissen fundoplication: results of a meta-analysis
Control 
of GER*
Visick
gradingt
Remaining in 
remission J ‘Healing capacity’§
67%-92% 83%-100% 75%-100% 73%-100%
n\\ = 1019 n = 159 n = 660 n = 221
Refs. 35,37,39-43, Refs. 36,43,49 Refs. 23,33,35-39, Refs. 23,34,36,48,
46,47,52-54 41,44-46,48-51 50,51
* Control of gastroesophageal reflux is assessed in various ways and measured with various instruments: good to excellent results range 
from 67% lo 92%. 
t Grades I and II.
X Central effect factor: percentage of patients remaining in full remission of esophagitis during the entire follow-up period of the 
respective studies.
§ Percentage of patients who had esophagitis (grade I or worse) pre-operatively and who remained in full remission post-operatively.
| Total number of subjects participating in the respective studies.
gastroscopy: 66 patients (98.5%) had normal mucosa (grade 
0), and one patient had esophagitis grade I without symptoms. 
Analysis of data showed that utilization of resources and 
duration of the operation and admission developed along a 
‘learning curve’. The most recent data indicate that the costs 
of the operation are very much similar to those of the ‘open’ 
variant. Hospital stay, however, is significantly reduced to 2-
3 days, including pre-operative stay. On the basis of 
effectiveness reported and the reduction of costs due to 
hospital admission (from 10 to 3 days), the cost effectiveness 
of the laparoscopic Nissen fundoplication is Dfl. 4748 (4676/
0.985).
Comparison of medical maintenance therapy versus surgery 
Since costs and effects are expressed in the same units, the
cost effectiveness of the respective therapies can now be 
compared. In Fig. 2 the cost effectiveness in time of the three 
therapeutic options is illustrated.
The break-even point in time is the number of years at 
which the cost effectiveness of the alternatives are equal. If 
medical maintenance treatment with omeprazole is to last 
longer than approximately 4 years, it is more cost-effective to 
operate (open Nissen). If medical treatment is compared with 
the laparoscopic Nissen fundoplication, this break-even point 
is approximately 1.4 years; this shift is mainly due to a 
reduction in hospital stay. From an economic point of view, if 
one knows in advance that a patient requires medical therapy 
for, say, 10 years, a Nissen fundoplication is the more cost- 
effective treatment for this patient. Substantial savings will
years
Fig. 2. Comparison of medical treatment with omeprazole versus the (laparoscopic) Nissen fundoplication, on the basis of cost effectiveness.
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Table III. Cost effectiveness of the Nissen fundoplication and the 
impact of discounting
Years
Cumulative
effects*
Cumulative
effects! C/E ratiot C/E ratio§
1 90.5 90.5 12,356 12,356
2 176.7 181.7 6329 6156
3 258.8 275.0 4321 4066
4 337.0 368.3 3319 3036
5 411.4 461.7 2718 2422
10 733.8 928,3 1524 1205
15 986.3 1395.0 1134 802
20 1184.2 1861.6 944 601
25 1339.3 2328.3 835 480
30 1460.8 2794.9 766 400
* Cumulative effects, discounted at a 5% rate, 
t  Cumulative effects, undiscounted, 
j  Cost effectiveness, based on discounted effects (5%). 
§ Cost effectiveness, based on un discounted effects.
occur after 4 years (after 1.4 years in case of a laparoscopic 
Nissen fundoplication).
Sensitivity analysis
Since calculations are based on assumptions and modeling, 
uncertainty should be resolved by means of sensitivity 
analysis (Fig, 3). The influence of changing a single 
assumption or estimation on the final result (that is, the 
break-even point) is displayed here.
It is notable that fairly sensitive assumptions such as 
duration of admission of the open Nissen procedure and the
price of a daily dose of omeprazole are well documented and 
thus certain. On the other hand, the estimations that were less 
certain are fairly insensitive. For example, a 25% change in 
costs of gastroscopy has no significant effect on the break­
even point. It has recently been claimed that endoscopy 
should only be performed once every 5 years; this would not 
radically change our results and conclusions. The insensitivity 
of the discount factor can be explained by the fact that the 
break-even points are reached in fairly short time periods: the 
impact of discounting becomes increasingly evident when 
longer time spans are involved.
DISCUSSION
Many articles have been published on the efficacy of anti­
reflux treatment, but only a few are focused on cost 
effectiveness. Bate (60) compared two medical alternatives: 
treatment of reflux esophagitis with either omeprazole or H2- 
antagonists (ranitidine). He concluded that omeprazole is the 
more cost-effective option: the higher costs of omeprazole 
are more than compensated for by its higher effectiveness 
with regard of healing esophagitis and relieving symptoms. 
More recently, Barradell & McTavish assessed the cost 
effectiveness of omeprazole in the treatment of reflux 
esophagitis and duodenal ulcer (61) and concluded that 
omeprazole is a cost-effective treatment option both in 
healing esophagitis and in preventing relapses. The results of 
these studies cannot be compared with our findings since
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Fig. 3. Results of sensitivity analysis: the influence of changing single variables on the break-even point.
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costs and drug regimens are not comparable; however, with 
regard to assessing drug effectiveness, findings and assump­
tions do agree well with this study. Most recently, health- 
economic aspects in the management of acid-related diseases 
were the topic of discussion during a symposium held in 
Paris (62). The importance of economic evaluation and its 
role in decision-making and the need for standardization 
were emphasized. The presented studies (duodenal ulcer and 
persistent GERD) confirm the above findings, but these 
studies were not set up to compare medical treatment with 
anti-reflux surgery. Studies concerning the cost effectiveness 
of anti-reflux surgery were not found.
Cost-effectiveness studies are often based on modeling and 
estimating instead of measuring actual costs, alongside 
clinical trials. There are two major shortcomings in assessing 
cost effectiveness retrospectively by means of modeling. 
First, data on many cost factors are lacking. Data on some 
core factors, such as in this case the amount of medication 
prescribed or the average duration of admission, are available 
or can be estimated with reasonable accuracy. But data on 
other relevant factors such as the costs due to treatment 
failures, side effects, or absenteeism from work are often 
unavailable. Secondly, factors indicating effectiveness are not 
uniform. Individual studies are seldom set up to be used for 
comparison across studies. In this particular case the outcome 
of medical treatment is, as mentioned, different from the 
outcome of surgery. A single measure of effectiveness is 
defined (retaining patients in remission), but that does not 
make results truly comparable; again it is stated that the 
results are restricted to this single measure.
Despite the above-mentioned disadvantages these compari­
sons do have informational value. For example, the fact that 
patients may have postoperative morbidity or even mortality 
due to surgery is not accounted for in this study. Suppose, for 
the purpose of simplicity, that the only negative outcome of 
surgery would be that 2 of 1000 patients die as a result of the 
Nissen operation. The outcome of studies like this makes it 
possible to weigh these negative effects against the possible 
savings: substituting surgery for omeprazole in 1000 patients 
will generate savings in excess of 20 million guilders in 10 
years. The question remains: is this worth giving up two lives 
for? This may sound very harsh and unethical, but (allocation) 
decisions at local and national levels implicitly value such 
negative effects. Economic evaluations only elicit these 
valuations and make them explicit, without being judge­
mental.
There are some significant advantages of assessing cost 
effectiveness in a manner such as presented in this study. For 
one, it may serve as a means to estimate the cost-effective 
potential of a new therapy, even in a very early stage in the 
product life cycle of a therapy/intervention, In this instance a 
laparoscopically performed Nissen operation is tested in an 
early stage of development. Although a broad range of 
uncertainty is introduced in the sensitivity analysis, our 
findings indicate that surgery and especially laparoscopic
surgery is a cost-effective alternative for medical treatment 
and that substantial savings might occur if the present medical 
therapy is replaced. These findings are a strong advocate for 
cost-effectiveness studies of medical treatment versus laparo­
scopic surgery in clinical trials.
Modeling with the aid of a spreadsheet may be of use in 
determining threshold levels for either costs or effects in the 
comparison of therapies. New cost-effectiveness ratios due to 
fluctuation in prices or due to new data on effectiveness or 
protocols can easily be computed.
CONCLUSIONS AND RECOMMENDATIONS
Although caution is required in drawing substantial conclu­
sions, it appears that surgery (Nissen fundoplication) is a 
cost-effective treatment option in patients with severe or 
refractory GERD as compared with medical treatment 
(omeprazole) if this medical treatment is to last longer than 
approximately 4 years. If effectiveness is solely expressed in 
terms of keeping patients in full remission of their 
esophagitis, changing to surgery will lead to substantial 
savings from this point in time onwards. A laparoscopic 
Nissen procedure might be even more cost effective: due to a 
substantial reduction in hospital stay, a laparoscopic Nissen 
fundoplication is more cost effective than medical treatment 
if this treatment is to last longer than approximately 17 
months. Besides potential clinical superiority owing to a 
decrease in postoperative morbidity, laparoscopic surgery is 
likely to be superior from a health-economic perspective. A 
well-designed clinical trial in which medical maintenance 
treatment is compared with the laparoscopic Nissen fundo­
plication should be set up. It should incorporate an economic 
evaluation. All relevant cost factors, including costs due to 
side effects and morbidity and so-called indirect costs due to 
production losses, should be measured prospectively and 
valued properly (cost prices). Quality of life and patient 
preferences should be assessed by means of generic (utilities) 
and disease-specific instruments.
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